City of Hope | Strategic Alliance Partners

Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.

Two cases of cytokine release syndrome occurred during the first cycle of step-up dosing; however, both were considered non-severe and were treated without the need of tocilizumab, admission to the ICU or use of vasopressors.

Anita Johnson, MD, FACS, discusses existing disparities in cancer, studies that have helped to shed further light on the issue, and ongoing efforts being made to improve outcomes in all patients.

Although the COVID-19 vaccine rollout is unprecedented in speed and scope, the process of postapproval surveillance has been shown to be robust and should serve as a source of reassurance to the public regarding the effectiveness of the initial and follow-up review process.

Natasha Garg, DO, discusses selecting between antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

The challenges of assessing COVID-19 vaccines shows that events in the real world may differ from those of a formal objective scientific analysis, especially in a setting where such evaluations of necessity involve very small numbers.

Erminia Massarelli, MD, MS, PhD, shares key updates in immunotherapy and targeted treatment for patients with NSCLC

Ravi Salgia, MD, PhD, discusses pivotal trials that have shaken up the SCLC treatment paradigm and novel immunotherapy regimens under investigation.

Dan J. Raz, MAS, MD, discusses the effects of COVID-19 on lung cancer screening.

Natasha Garg, DO, discusses the impact of antiandrogens in the treatment of patients with nonmetastatic CRPC, shared advice for choosing among the available options, and projected what the future paradigm might look like.

Joseph Mikhael, MD, MEd, FRCPC, FACP, discussed how melphalan flufenamide could potentially shift the treatment paradigm for patients with multiple myeloma.

The current endorsement of 3 COVID-19 vaccines in the United States, with several additional products pending FDA review, in less than 1 year from the identification of the structure of the COVID-19 virus is simply remarkable.

Sumanta K. Pal, MD, details ongoing research efforts dedicated to providing additional therapeutic options for patients with RCC in the second-line setting and beyond.

Tanya Dorff, MD, discusses how the FDA approvals of olaparib and rucaparib have paved the way for additional research with PARP inhibitors in metastatic castration-resistant prostate cancer.

Tanya Dorff, MD, discusses the importance of somatic testing in metastatic castration-resistant prostate cancer.

Evolving data provide provocative support for the relevance of an optimistic vs a pessimistic perspective in influencing outcomes in serious malignant conditions.

The field of triple-negative breast cancer is pushing to improve treatment by answering questions regarding biomarkers of response, defining the utility of neoadjuvant approaches, and exploring potential combinations with checkpoint inhibitors and PARP inhibitors.

The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.

Maurie Markman, MD, discusses how privacy and consent in clinical cancer trials have improved over the years.

February 8, 2021 — Narsoplimab demonstrated clinical activity and a favorable survival benefit in patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy, according to updated results of a pivotal phase 2 trial.

Introduced today in the state Senate, legislation details six rights for every cancer patient in California.

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

In a pandemic, the public and its leaders yearn for relatively simple answers that can lead to solutions and forceful actions such as preventing serious infection and hospitalizations, treating active illness, and developing safe and effective vaccines quickly made available to the public.

Tanya Siddiqi, MD, discusses the rationale to evaluate CAR T-cell therapy in chronic lymphocytic leukemia.

The repercussions of delays in diagnosing cancer, either through screening or the presence of early symptoms, and of required modifications in standard-of-care management paradigms in the COVID-19 era are only now beginning to be fully appreciated.

City of Hope is investigating an innovative treatment for cancer patients with COVID-19 by repurposing leflunomide, an anti-inflammatory drug for rheumatoid arthritis that is inexpensive and has few serious side effects, in a new clinical trial.

Sumanta K. Pal, MD, discusses the safety profile of cabozantinib in combination with atezolizumab in advanced renal cell carcinoma.

The comprehensive cancer center has also dosed its first patient in chlorotoxin CAR T cell therapy trial.

Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.

Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.